One of the world’s largest pharmaceutical companies needed insights into how large-scale adoption of comparative effectiveness models in the U.S. could affect its core business strategy, but faced reluctance among U.S. stakeholders about its use.


Quintiles conducted an exhaustive analysis into global and U.S. responses to the use of comparative effectiveness research, identifying key signals to help the customer recognize risk scenarios. 


Today, the customer is able to identify key business trends as they emerge in the area of comparative effectiveness, while having the insights to respond quickly to maintain a competitive advantage in the changing environment of the New Health.